Loading clinical trials...
Loading clinical trials...
A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Conditions
Interventions
Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
Cinrebafusp alfa (PRS-343) in combination with tucatinib
Locations
5
United States
Sansum Clinic
Santa Barbara, California, United States
Maryland Oncology-Hematology
Silver Spring, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Samsung Medical Center
Seoul, South Korea
Start Date
November 1, 2021
Primary Completion Date
February 1, 2023
Completion Date
February 1, 2023
Last Updated
September 8, 2022
NCT06532006
NCT06846996
NCT05982834
NCT05955833
NCT05619016
Lead Sponsor
Pieris Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions